Splendil Er en es it fr

Splendil Er Brand names, Splendil Er Analogs

Splendil Er Brand Names Mixture

  • No information avaliable

Splendil Er Chemical_Formula


Splendil Er RX_link


Splendil Er fda sheet

Splendil_Er FDA

Splendil Er msds (material safety sheet)

Splendil Er Synthesis Reference

R. P. Pioch, U.S. Pat. 4,375,547 (1982)

Splendil Er Molecular Weight

331.46 g/mol

Splendil Er Melting Point

203 oC

Splendil Er H2O Solubility


Splendil Er State


Splendil Er LogP


Splendil Er Dosage Forms

Capsule (150, 300 mg)

Splendil Er Indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.

Splendil Er Pharmacology

Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.

Splendil Er Absorption

Rapid (bioavailability of nizatidine exceeds 70%)

Splendil Er side effects and Toxicity

Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.

Splendil Er Patient Information

Splendil Er Organisms Affected

Humans and other mammals